447 related articles for article (PubMed ID: 27777773)
1. Antitumor activity of nivolumab on hemodialysis after renal allograft rejection.
Ong M; Ibrahim AM; Bourassa-Blanchette S; Canil C; Fairhead T; Knoll G
J Immunother Cancer; 2016; 4():64. PubMed ID: 27777773
[TBL] [Abstract][Full Text] [Related]
2. Checkpoint inhibitors in chronic kidney failure and an organ transplant recipient.
Herz S; Höfer T; Papapanagiotou M; Leyh JC; Meyenburg S; Schadendorf D; Ugurel S; Roesch A; Livingstone E; Schilling B; Franklin C
Eur J Cancer; 2016 Nov; 67():66-72. PubMed ID: 27614165
[TBL] [Abstract][Full Text] [Related]
3. Donor-derived cell-free DNA detects kidney transplant rejection during nivolumab treatment.
Hurkmans DP; Verhoeven JGHP; de Leur K; Boer K; Joosse A; Baan CC; von der Thüsen JH; van Schaik RHN; Mathijssen RHJ; van der Veldt AAM; Hesselink DA
J Immunother Cancer; 2019 Jul; 7(1):182. PubMed ID: 31300068
[TBL] [Abstract][Full Text] [Related]
4. PD 1 checkpoint inhibition in solid organ transplants: 2 sides of a coin - case report.
Goldman JW; Abdalla B; Mendenhall MA; Sisk A; Hunt J; Danovitch GM; Lum EL
BMC Nephrol; 2018 Aug; 19(1):210. PubMed ID: 30126374
[TBL] [Abstract][Full Text] [Related]
5. Pembrolizumab for metastatic melanoma in a renal allograft recipient with subsequent graft rejection and treatment response failure: a case report.
Kwatra V; Karanth NV; Priyadarshana K; Charakidis M
J Med Case Rep; 2017 Mar; 11(1):73. PubMed ID: 28315636
[TBL] [Abstract][Full Text] [Related]
6. Acute renal transplant rejection following nivolumab therapy for metastatic melanoma.
Tan B; Baxter M; Casasola R
BMJ Case Rep; 2021 Feb; 14(2):. PubMed ID: 33558380
[TBL] [Abstract][Full Text] [Related]
7. Immune Checkpoint Inhibitors in Organ Transplant Patients.
Kittai AS; Oldham H; Cetnar J; Taylor M
J Immunother; 2017 Sep; 40(7):277-281. PubMed ID: 28719552
[TBL] [Abstract][Full Text] [Related]
8. Combination checkpoint blockade for metastatic cutaneous malignancies in kidney transplant recipients.
Trager MH; Coley SM; Dube G; Khan S; Ingham M; Samie FH; Geskin LJ; McDonnell D; Brouder D; Saenger Y; Carvajal R
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32503950
[TBL] [Abstract][Full Text] [Related]
9. Programmed Cell Death 1 (PD-1) Inhibitors in Renal Transplant Patients with Advanced Cancer: A Double-Edged Sword?
Lai HC; Lin JF; Hwang TIS; Liu YF; Yang AH; Wu CK
Int J Mol Sci; 2019 May; 20(9):. PubMed ID: 31058839
[TBL] [Abstract][Full Text] [Related]
10. Acute renal allograft rejection after immune checkpoint inhibitor therapy for metastatic melanoma.
Spain L; Higgins R; Gopalakrishnan K; Turajlic S; Gore M; Larkin J
Ann Oncol; 2016 Jun; 27(6):1135-1137. PubMed ID: 26951628
[TBL] [Abstract][Full Text] [Related]
11. Severe Allograft Rejection and Autoimmune Hemolytic Anemia After Anti-PD1 Therapy in a Kidney Transplanted Patient.
Deltombe C; Garandeau C; Renaudin K; Hourmant M
Transplantation; 2017 Sep; 101(9):e291. PubMed ID: 29633980
[No Abstract] [Full Text] [Related]
12. Efficacy and Safety of Nivolumab in Patients With BRAF V600 Mutant and BRAF Wild-Type Advanced Melanoma: A Pooled Analysis of 4 Clinical Trials.
Larkin J; Lao CD; Urba WJ; McDermott DF; Horak C; Jiang J; Wolchok JD
JAMA Oncol; 2015 Jul; 1(4):433-40. PubMed ID: 26181250
[TBL] [Abstract][Full Text] [Related]
13. The successful use of pembrolizumab in a renal transplant recipient with metastatic melanoma.
Hanna DL; Law SJ; Merrick SA; Heptinstall L; Bass P; Dupont P; Sheri A
Melanoma Res; 2020 Jun; 30(3):321-324. PubMed ID: 31764435
[TBL] [Abstract][Full Text] [Related]
14. Responses of metastatic basal cell and cutaneous squamous cell carcinomas to anti-PD1 monoclonal antibody REGN2810.
Falchook GS; Leidner R; Stankevich E; Piening B; Bifulco C; Lowy I; Fury MG
J Immunother Cancer; 2016; 4():70. PubMed ID: 27879972
[TBL] [Abstract][Full Text] [Related]
15. Nivolumab-induced autoimmune diabetes mellitus presenting as diabetic ketoacidosis in a patient with metastatic lung cancer.
Godwin JL; Jaggi S; Sirisena I; Sharda P; Rao AD; Mehra R; Veloski C
J Immunother Cancer; 2017; 5():40. PubMed ID: 28515940
[TBL] [Abstract][Full Text] [Related]
16. Poor Outcomes With the Use of Checkpoint Inhibitors in Kidney Transplant Recipients.
Venkatachalam K; Malone AF; Heady B; Santos RD; Alhamad T
Transplantation; 2020 May; 104(5):1041-1047. PubMed ID: 31415036
[TBL] [Abstract][Full Text] [Related]
17. Development of psoriatic arthritis during nivolumab therapy for metastatic non-small cell lung cancer, clinical outcome analysis and review of the literature.
Ruiz-Bañobre J; Pérez-Pampín E; García-González J; Gómez-Caamaño A; Barón-Duarte FJ; López-López R; Vázquez-Rivera F
Lung Cancer; 2017 Jun; 108():217-221. PubMed ID: 28625638
[TBL] [Abstract][Full Text] [Related]
18. Nivolumab: A Review in Advanced Melanoma.
Scott LJ
Drugs; 2015 Aug; 75(12):1413-24. PubMed ID: 26220912
[TBL] [Abstract][Full Text] [Related]
19. Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients: an institutional experience and a systematic review of the literature.
Abdel-Wahab N; Safa H; Abudayyeh A; Johnson DH; Trinh VA; Zobniw CM; Lin H; Wong MK; Abdelrahim M; Gaber AO; Suarez-Almazor ME; Diab A
J Immunother Cancer; 2019 Apr; 7(1):106. PubMed ID: 30992053
[TBL] [Abstract][Full Text] [Related]
20. Use of the PD-1 Pathway Inhibitor Nivolumab in a Renal Transplant Patient With Malignancy.
Boils CL; Aljadir DN; Cantafio AW
Am J Transplant; 2016 Aug; 16(8):2496-7. PubMed ID: 26988410
[No Abstract] [Full Text] [Related]
[Next] [New Search]
